{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:07:01Z","timestamp":1788538021928,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022294","name":"National Taiwan University Hospital Yun Lin Branch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-400-005"],"award-info":[{"award-number":["113-2314-B-400-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.afos.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:55:21Z","timestamp":1764392121000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-7718","authenticated-orcid":false,"given":"Ming-Hung","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-8063","authenticated-orcid":false,"given":"Tian-Sin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1616-0178","authenticated-orcid":false,"given":"Chia-Che","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-3149","authenticated-orcid":false,"given":"Tzu-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-2220","authenticated-orcid":false,"given":"Hung-Kuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-9520","authenticated-orcid":false,"given":"Chih-Chien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-2489","authenticated-orcid":false,"given":"Yi-Chien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0731-1880","authenticated-orcid":false,"given":"Ning-Huei","family":"Sie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-2438","authenticated-orcid":false,"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-872X","authenticated-orcid":false,"given":"Shau-Huai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2025.11.002_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.afos.2025.11.002_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2025.11.002_bib5","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.afos.2025.11.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"AMERICAN association of clinical endocrinologists\/AMERICAN college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal OSTEOPOROSIS-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.afos.2025.11.002_bib7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society\u2217 clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2025.11.002_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and Teriparatide Follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.afos.2025.11.002_bib11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib12","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for Postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","article-title":"Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05","volume":"34","author":"Mori","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2025.11.002_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, Double-Blind, Phase 2, Parallel Group Study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib16","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1210\/clinem\/dgz163","article-title":"Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT","volume":"105","author":"Ramchand","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2025.11.002_bib20","article-title":"Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.afos.2025.11.002_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2025.11.002_bib22","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jbmr.4409","article-title":"Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial","volume":"36","author":"Brown","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.afos.2025.11.002_bib25","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.afos.2025.11.002_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.afos.2025.11.002_bib29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib30","first-page":"413","article-title":"Discrimination of changes in osteoporosis outcomes","volume":"28","author":"Cranney","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.afos.2025.11.002_bib31","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1210\/clinem\/dgae484","article-title":"The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis","volume":"110","author":"Hartz","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2025.11.002_bib33","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jbmr.2855","article-title":"Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis","volume":"31","author":"Zebaze","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib34","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.afos.2025.11.002_bib35","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2025.11.002_bib36","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","author":"Tsujimoto","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.afos.2025.11.002_bib39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1210\/jc.2013-4105","article-title":"Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa","volume":"99","author":"Fazeli","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2025.11.002_bib40","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2025.11.002_bib41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525525001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525525001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:17:57Z","timestamp":1766168277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525525001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2405525525001517"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2025.11.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}